"...While the potential of stem cell science is exciting the bottom line remains that Mesoblast is burning through capital at prodigious rates with little in the way of commercial success.
...
Kentgrove will also receive 4.5% of all funds raised just for arranging the placement of shares in what looks a good deal for Kentgrove and bad deal for retail shareholders.
...
Given the large cash outflows, latest capital management initiatives and substantial risk around the uncertainty of clinical trial results there’s not much to like about Mesoblast as an investment in my opinion."
http://www.********.au/2016/07/04/mesoblast-limited-moves-to-reassure-investors/#
(Incoming!)
Commentary
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.23%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.04 | $14.57M | 13.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 21024 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 241 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |